March 11, 2005 On Friday, investors paid more attention to macro economic news (oil prices, trade deficits) than optimistic forecasts from individual companies (Intel), sending prices steadily lower all day in a prolonged slide. The Centient Biotech 200 lost 35.54 points (1.12%) to 3140. We talk about a Phase II failure for Savient, a big contract for Xoma, a downgrade for Forest, a delay for Bradley Pharma’s financials while it examines its auditing procedures, a big counter-trend run-up for Titan Pharma, and some Medicare pricing problems for NitroMed’s new drug. More details...
